First came the wave of new agents aimed at resistant gram positive organisms, now the first novel serine beta-lactam/beta lactamase combination with expanded activity against multidrug resistant gram negative agents.The Anti-Infective Drug Advisory Committee (AIDAC) Meeting meets December 5, 2014 to discuss the new drug application (NDA) for ceftazidime-avibactam, submitted by Cerexa Inc., for the proposed indications of: Complicated Intra-abdominal Infections, Complicated Urinary Tract Infections, including Acute Pyelonephritis and Limited Use Indication: Aerobic Gram-negative Infections with Limited Treatment Options.